John W. Smither - 31 Aug 2023 Form 4 Insider Report for Arcutis Biotherapeutics, Inc. (ARQT)

Role
Chief Financial Officer
Signature
/s/ Masaru Matsuda, Attorney-in-Fact for John W. Smither
Issuer symbol
ARQT
Transactions as of
31 Aug 2023
Net transactions value
$0
Form type
4
Filing time
05 Sep 2023, 21:38:43 UTC
Previous filing
22 Jun 2023
Next filing
13 Sep 2023
SEC
View on sec.gov

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction ARQT Stock Option (right to buy) Award $0 +125,000 $0.000000 125,000 31 Aug 2023 Common Stock 125,000 $8.54 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The option vests 1/48 of the total shares in equal monthly installments over a four year period, beginning September 30, 2023, subject to the Reporting Person's continuous provision of services to the Issuer on each vesting date. The option contains an early-exercise provision and is exercisable as to unvested shares, subject to the Issuer's right of repurchase.